PBYI Q1 2024 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M-17.1% YoY

Gross Profit

$33M75.5% margin

Operating Income

-$2M-5.3% margin

Net Income

-$5M-11.0% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-39.4%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$214M

Total Liabilities

$163M

Stockholders' Equity

$51M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$53M	-17.1%
Gross Profit	$33M	$40M	-16.5%
Operating Income	-$2M	$4M	-152.7%
Net Income	-$5M	$1M	-443.7%

Revenue Segments

Product

$40M92%

Royalty

$3M8%